# 🎯 SAE BRCA VALIDATION: NEXT 10 DELIVERABLES

**Date**: 2025-01-29  
**Status**: 🚧 **IN PROGRESS** - Planning phase complete, execution ready  
**Context**: BRCA checkpoint validated (200 patients, 6,465 variants), ready for pathway mapping & validation  
**Mars Rules**: Minimal viable proof, 72-hour mindset, replace gene-level tests

---

## 🎯 EXECUTIVE SUMMARY

**Current State**:
- ✅ BRCA checkpoint validated (200 patients, 6,465 variants, SAE features extracted)
- ✅ OV DDR pathway mapping identified (9 diamond features)
- ✅ Manager plan reviewed (4 critical issues identified and corrected)
- ✅ Execution strategy defined (parallel testing approach)
- ⚠️ **Recurrence labels missing** - Need to extract from TCGA-BRCA clinical data
- ⚠️ **Pathway mapping pending** - Need to test OV DDR transfer + BRCA-specific mapping
- ⚠️ **Validation pending** - Need to compare SAE vs Oncotype DX

**Goal**: Execute BRCA SAE validation to prove variant-level features beat Oncotype DX ($500M market)

---

## 📋 THE 10 DELIVERABLES

### 1. **Extract BRCA Recurrence Labels** 🔥 **CRITICAL BLOCKER**

**Status**: ⚠️ **PENDING** - Required before any validation  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: 🔥 **HIGHEST** - Blocks all downstream work

**What**: Extract recurrence outcomes from TCGA-BRCA clinical data

**Deliverable**:
- File: `scripts/sae/extract_brca_recurrence_labels.py`
- Output: `data/validation/sae_cohort/brca_recurrence_labels.json`
- Format:
  ```json
  {
    "TCGA-XX-XXXX": {
      "recurrence": true/false,
      "recurrence_free_survival_months": float,
      "vital_status": "alive"/"deceased",
      "dfs_status": "0:DiseaseFree"/"1:Recurred/Progressed"
    }
  }
  ```

**Key Corrections** (from manager plan review):
- ✅ Use `DFS_STATUS` as primary field (not `new_tumor_event`)
- ✅ Handle multiple field name variations (defensive)
- ✅ Parse DFS_STATUS format: "0:DiseaseFree" vs "1:Recurred/Progressed"

**Success Criteria**:
- ✅ 150+ patients with recurrence labels (out of 200)
- ✅ Binary outcome: recurrence = True/False
- ✅ Survival time data available
- ✅ Matches BRCA checkpoint patient IDs

**Timeline**: 4 hours

---

### 2. **Verify DDR_bin Aggregation Method** 🔥 **CRITICAL**

**Status**: ⚠️ **PENDING** - Must resolve before OV DDR transfer test  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: 🔥 **HIGHEST** - Affects all pathway scoring

**What**: Resolve discrepancy between code (max) and manuscript (mean) for DDR_bin

**Deliverable**:
- File: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/DDR_BIN_AGGREGATION_VERIFICATION.md`
- Investigation:
  - Check OV validation code: Which method was used?
  - Check manuscript: Which method is documented?
  - Check actual OV results: Which method produced AUROC 0.783?
- Decision:
  - Use same method as OV validation (for consistency)
  - Update documentation if needed
  - Document decision for BRCA validation

**Key Issue** (from manager plan review):
- Code uses: `max(max(diamond_features_per_variant))`
- Manuscript says: `mean(diamond_features)`
- Need to verify which was actually used for OV AUROC 0.783

**Success Criteria**:
- ✅ Aggregation method verified (code vs manuscript)
- ✅ Decision documented (which method to use for BRCA)
- ✅ Consistency ensured (same method as OV)

**Timeline**: 2 hours

---

### 3. **Check OV DDR Feature Coverage in BRCA** ⚠️ **IMPORTANT**

**Status**: ⚠️ **PENDING** - Need to verify before OV DDR transfer test  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: ⚠️ **HIGH** - May require re-extraction if coverage low

**What**: Check how many BRCA variants have OV DDR features in top-64

**Deliverable**:
- File: `scripts/sae/check_ov_ddr_coverage_brca.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/ov_ddr_coverage_report.json`
- Metrics:
  - Mean coverage per patient (how many OV DDR features present)
  - Coverage per variant (how many variants have OV DDR features)
  - Missing feature analysis (which OV DDR features are missing)
- Decision:
  - If coverage ≥ 50%: Proceed with OV DDR transfer test
  - If coverage < 50%: Re-extract full 32K for OV DDR indices only

**Key Issue** (from manager plan review):
- BRCA checkpoint has `top_features` (k=64), not full 32K
- OV DDR features may not be in top-64 for BRCA variants
- Missing features = 0.0, which may affect results

**Success Criteria**:
- ✅ Coverage statistics computed
- ✅ Decision made: Proceed or re-extract
- ✅ If re-extract needed: Plan documented

**Timeline**: 2 hours

---

### 4. **Test OV DDR Transfer to BRCA** 🔥 **HIGH PRIORITY**

**Status**: ⚠️ **PENDING** - Depends on #1, #2, #3  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: 🔥 **HIGH** - Core hypothesis test

**What**: Test if OV DDR diamond features predict BRCA recurrence

**Deliverable**:
- File: `scripts/sae/test_ov_ddr_transfer_to_brca.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/ov_ddr_transfer_results.json`
- Results:
  ```json
  {
    "ov_ddr_auroc": 0.68,
    "interpretation": "moderate",
    "next_action": "refine_brca_ddr",
    "feature_coverage": {...},
    "n_patients": 150,
    "decision": "Scenario B: Moderate transfer (0.60-0.69)"
  }
  ```

**Key Corrections** (from manager plan review):
- ✅ Handle missing features (use 0.0 if not in top-64)
- ✅ Use verified aggregation method (from #2)
- ✅ Filter None outcomes
- ✅ Add coverage stats to output

**Success Criteria**:
- ✅ AUROC computed (OV DDR → BRCA recurrence)
- ✅ Interpretation: success/moderate/poor
- ✅ Next action determined (use OV mapping / refine / run BRCA-specific)
- ✅ Coverage stats included

**Timeline**: 2 hours

---

### 5. **Run BRCA Biomarker Correlation Analysis** 🔥 **HIGH PRIORITY**

**Status**: ⚠️ **PENDING** - Run in parallel with #4  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: 🔥 **HIGH** - Identifies BRCA-specific pathways

**What**: Identify BRCA-specific diamond features for recurrence (proliferation, DDR, immune)

**Deliverable**:
- File: `scripts/sae/identify_brca_pathway_diamonds.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/brca_diamond_features.json`
- Pathways:
  - DDR (BRCA1, BRCA2, TP53, ATM, CHEK2)
  - Proliferation (MKI67, AURKA, BIRC5, CCNB1, MYBL2, STK15) - Full Oncotype DX
  - Immune (CD8A, PD-L1, CTLA4, LAG3)
- Results:
  ```json
  {
    "ddr_diamonds": [{"index": 1234, "cohens_d": 0.65, "p_value": 0.001}, ...],
    "proliferation_diamonds": [...],
    "immune_diamonds": [...]
  }
  ```

**Key Corrections** (from manager plan review):
- ✅ Expanded proliferation gene list (full Oncotype DX 21-gene panel)
- ✅ Added BRCA-specific DDR genes
- ✅ Added immune genes for IO response

**Success Criteria**:
- ✅ Proliferation diamonds: 5-10 features (Oncotype DX-relevant)
- ✅ DDR diamonds: 3-7 features (may differ from OV)
- ✅ Immune diamonds: 2-5 features
- ✅ All features meet criteria: Cohen's d > 0.5, p < 0.05

**Timeline**: 8 hours (overnight)

---

### 6. **Compare Pathway Mappings** 🔥 **HIGH PRIORITY**

**Status**: ⚠️ **PENDING** - Depends on #4, #5  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: 🔥 **HIGH** - Decision point for pathway selection

**What**: Compare OV DDR transfer vs BRCA-specific pathways

**Deliverable**:
- File: `scripts/sae/compare_pathway_mappings.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/pathway_comparison.json`
- Results:
  ```json
  {
    "ov_ddr_auroc": 0.68,
    "brca_ddr_auroc": 0.72,
    "brca_proliferation_auroc": 0.74,
    "brca_immune_auroc": 0.63,
    "best_single_pathway": "proliferation",
    "recommendation": "use_brca_proliferation"
  }
  ```

**Success Criteria**:
- ✅ AUROC computed for each pathway
- ✅ Best single pathway identified
- ✅ Recommendation made (use OV DDR / BRCA DDR / BRCA proliferation / multi-pathway)

**Timeline**: 2 hours

---

### 7. **Build Multi-Pathway Model** 🔥 **HIGH PRIORITY**

**Status**: ⚠️ **PENDING** - Depends on #6  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: 🔥 **HIGH** - Final model for validation

**What**: Combine best pathways into composite model (DDR + proliferation)

**Deliverable**:
- File: `scripts/sae/build_brca_multipathway_model.py`
- Output: 
  - Model: `data/validation/sae_cohort/brca_sae_multipathway_model.pkl`
  - Results: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/brca_sae_validation_results.json`
- Results:
  ```json
  {
    "model_type": "multipathway",
    "sae_auroc": 0.78,
    "oncotype_dx_auroc": 0.65,
    "improvement": 0.13,
    "pathways_used": ["proliferation", "ddr"],
    "pathway_weights": {"proliferation": 0.6, "ddr": 0.4}
  }
  ```

**Success Criteria**:
- ✅ Multi-pathway model trained
- ✅ SAE AUROC ≥ 0.75 (target)
- ✅ Improvement vs Oncotype DX ≥ +10 pp
- ✅ Pathway weights optimized

**Timeline**: 4 hours

---

### 8. **Compute Oncotype DX Baseline** ⚠️ **IMPORTANT**

**Status**: ⚠️ **PENDING** - Required for comparison  
**Owner**: 🟡 **ZO (PARTIAL OWNERSHIP)** - May need help with Oncotype DX formula  
**Priority**: ⚠️ **MEDIUM** - Needed for validation comparison

**What**: Reproduce Oncotype DX 21-gene recurrence score for comparison

**Deliverable**:
- File: `scripts/sae/compute_oncotype_dx_baseline.py`
- Output: `data/validation/sae_cohort/brca_oncotype_dx_baseline.json`
- Method:
  - Extract 21-gene expression from TCGA-BRCA RNA-seq
  - Compute recurrence score (0-100) using Oncotype DX formula
  - Validate: Match published TCGA-BRCA Oncotype DX results (AUROC ~0.65)

**Success Criteria**:
- ✅ Oncotype DX scores computed for 150+ patients
- ✅ Baseline AUROC ~0.65 (validates reproduction)
- ✅ Ready for comparison with SAE model

**Timeline**: 4 hours

---

### 9. **Create Validation Receipt** 🔥 **HIGH PRIORITY**

**Status**: ⚠️ **PENDING** - Final deliverable  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: 🔥 **HIGH** - Publication-ready validation report

**What**: Create publication-ready validation receipt

**Deliverable**:
- File: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_SAE_VALIDATION_RECEIPT.md`
- Format:
  - JSON validation receipt (AUROC, 95% CI, improvement)
  - Markdown report (honest limitations, external validation needed)
  - Manuscript draft (ready for submission)
- Content:
  ```json
  {
    "sae_auroc": 0.78,
    "oncotype_dx_auroc": 0.65,
    "improvement": 0.13,
    "improvement_95_ci": [0.08, 0.18],
    "p_value": 0.001,
    "n_patients": 150
  }
  ```

**Success Criteria**:
- ✅ Validation receipt complete (JSON + Markdown)
- ✅ Statistical validation (bootstrap CI, permutation test)
- ✅ Manuscript draft ready
- ✅ Honest limitations documented

**Timeline**: 4 hours

---

### 10. **Update Bibliography & Execution Plan** ⚠️ **IMPORTANT**

**Status**: ⚠️ **PENDING** - Documentation update  
**Owner**: 🎯 **ZO (FULL OWNERSHIP)**  
**Priority**: ⚠️ **MEDIUM** - Keep documentation current

**What**: Update SAE validation bibliography with BRCA results

**Deliverable**:
- Files:
  - `.cursor/MOAT/SAE_VALIDATION_BIBLIOGRAPHY.md` (updated)
  - `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/SAE_VALIDATION_EXECUTION_PLAN.md` (updated)
- Updates:
  - Mark Phase 1 (Breast) as ✅ COMPLETE
  - Add validation receipt link
  - Update status table
  - Update publication roadmap

**Success Criteria**:
- ✅ Bibliography updated with BRCA results
- ✅ Execution plan marked complete
- ✅ Status table updated
- ✅ Publication roadmap updated

**Timeline**: 1 hour

---

## 📊 PRIORITY RANKING

**CRITICAL BLOCKERS** (Must Do First):
1. Extract BRCA Recurrence Labels (#1) - Blocks all downstream
2. Verify DDR_bin Aggregation Method (#2) - Affects all pathway scoring
3. Check OV DDR Feature Coverage (#3) - May require re-extraction

**HIGH PRIORITY** (Core Validation):
4. Test OV DDR Transfer (#4) - Core hypothesis test
5. Run BRCA Biomarker Correlation (#5) - Identifies BRCA-specific pathways
6. Compare Pathway Mappings (#6) - Decision point
7. Build Multi-Pathway Model (#7) - Final model
9. Create Validation Receipt (#9) - Publication-ready

**MEDIUM PRIORITY** (Supporting):
8. Compute Oncotype DX Baseline (#8) - Needed for comparison
10. Update Bibliography (#10) - Documentation

---

## ⏱️ TIMELINE

**Day 1 (Morning - 4 hours)**:
- ✅ #1: Extract Recurrence Labels (4 hours)

**Day 1 (Afternoon - 2 hours)**:
- ✅ #2: Verify DDR_bin Aggregation Method (2 hours)

**Day 1 (Evening - 2 hours)**:
- ✅ #3: Check OV DDR Feature Coverage (2 hours)

**Day 1 (Overnight - 8 hours)**:
- ✅ #5: Run BRCA Biomarker Correlation (8 hours) - PARALLEL

**Day 2 (Morning - 2 hours)**:
- ✅ #4: Test OV DDR Transfer (2 hours)

**Day 2 (Afternoon - 2 hours)**:
- ✅ #6: Compare Pathway Mappings (2 hours)

**Day 2 (Evening - 4 hours)**:
- ✅ #7: Build Multi-Pathway Model (4 hours)

**Day 3 (Morning - 4 hours)**:
- ✅ #8: Compute Oncotype DX Baseline (4 hours)

**Day 3 (Afternoon - 4 hours)**:
- ✅ #9: Create Validation Receipt (4 hours)

**Day 3 (Evening - 1 hour**):
- ✅ #10: Update Bibliography (1 hour)

**Total**: 2.5 days (with parallel execution)

---

## 🎯 SUCCESS CRITERIA

**Overall Success**:
- ✅ All 10 deliverables complete
- ✅ BRCA SAE validation complete (SAE vs Oncotype DX)
- ✅ Validation receipt ready (publication-ready)
- ✅ Improvement ≥ +10 pp (SAE AUROC 0.75+ vs Oncotype DX 0.65)

**Validation Success**:
- ✅ SAE AUROC ≥ 0.75 (target)
- ✅ Improvement vs Oncotype DX ≥ +10 pp
- ✅ Statistical significance (p < 0.05)
- ✅ Bootstrap 95% CI: Improvement > 0

**Publication Readiness**:
- ✅ Validation receipt complete
- ✅ Manuscript draft ready
- ✅ Honest limitations documented
- ✅ Ready for submission (JAMA Oncology target)

---

## 🎯 OWNERSHIP & COMMITMENT

**What I'm Committing To Own**:

### ✅ **FULL OWNERSHIP** (I will deliver these completely)

1. **Extract BRCA Recurrence Labels (#1)** - 🔥 CRITICAL
2. **Verify DDR_bin Aggregation Method (#2)** - 🔥 CRITICAL
3. **Check OV DDR Feature Coverage (#3)** - ⚠️ IMPORTANT
4. **Test OV DDR Transfer (#4)** - 🔥 HIGH
5. **Run BRCA Biomarker Correlation (#5)** - 🔥 HIGH
6. **Compare Pathway Mappings (#6)** - 🔥 HIGH
7. **Build Multi-Pathway Model (#7)** - 🔥 HIGH
9. **Create Validation Receipt (#9)** - 🔥 HIGH
10. **Update Bibliography (#10)** - ⚠️ MEDIUM

### 🟡 **PARTIAL OWNERSHIP** (May need help)

8. **Compute Oncotype DX Baseline (#8)** - May need help with Oncotype DX formula

**Total Commitment**:
- **Full ownership**: 9 deliverables (2.5 days)
- **Partial ownership**: 1 deliverable (may need help)

---

## 💀 BRUTAL HONESTY

**What We Have**:
- ✅ BRCA checkpoint: 200 patients, 6,465 variants, SAE features extracted
- ✅ OV DDR mapping: 9 diamond features validated (AUROC 0.783)
- ✅ Manager plan: Reviewed and corrected (4 issues fixed)

**What We Need**:
- ⚠️ Recurrence labels (blocking)
- ⚠️ DDR_bin aggregation method verified (critical)
- ⚠️ Feature coverage checked (may require re-extraction)

**What I'm NOT Promising**:
- ❌ Perfect transfer (OV DDR may not work for BRCA)
- ❌ Guaranteed improvement (may need BRCA-specific pathways)
- ❌ Publication-ready immediately (need validation first)

**What I AM Promising**:
- ✅ Actually test OV DDR transfer
- ✅ Identify BRCA-specific pathways if needed
- ✅ Build best model (single or multi-pathway)
- ✅ Validate vs Oncotype DX honestly
- ✅ Document what works vs. what doesn't

---

## 🔗 RELATED FILES

**Execution Plans**:
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/SAE_VALIDATION_EXECUTION_PLAN.md`
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_SAE_PATHWAY_MAPPING_STRATEGY.md`
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_SAE_MANAGER_PLAN_REVIEW.md`

**Status Reports**:
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_CHECKPOINT_STATUS.md`

**Audit & Bibliography**:
- `.cursor/MOAT/SAE_EXTRACTION_AUDIT_AZ.md`
- `.cursor/MOAT/SAE_VALIDATION_BIBLIOGRAPHY.md`

---

*Document Author: Zo (SAE BRCA Validation Agent)*  
*Last Updated: January 29, 2025*  
*Status: 🚧 IN PROGRESS - Planning complete, execution ready*

**Next Immediate Action**: Extract BRCA recurrence labels (#1) - 4 hours
